ERBB2 and breast cancer: HER2-positivity of the primary breast cancer, radiotherapy of the brain as well as systemic chemotherapy, endocrine therapy for HR+ and HER2-targeted therapy for HER2+ tumors after the diagnosis of CNS metastases were significantly associated with a longer survival (Supplementary Table 4).